Mark Fendrick, MD, Discusses Value-Based Insurance Design
Dr. Mark Fendrick, MD, Professor of Medicine and Health Management and Policy, Schools of Medicine and Public Health, University of Michigan, Co-Editor-in-Chief, The American Journal of Managed Care, says that there are levers organizations and stakeholders can pull to achieve the goal of improving quality and value in cancer care. Dr. Fendrick discusses the importance of combining the supply side, or how you pay doctors, and the demand side of value, or consumer engagement. Dr. Fendrick also says that the goal of improved health and cost containment can be achieved when the two sides are combined.
This video was taken on November 16 at AJMC's Translating Evidence-Based Research Into Value-Based Decisions in Oncology.
Peter Salgo, MD, and Ira M. Klein, MD, MBA, FACP, discuss the treatment of prostate cancer with androgen-deprivation therapy and note that additional research is necessary to help determine which patient populations are at highest risk for developing resistance following ADT.
During this opening segment of a one-on-one interview series, Peter Salgo, MD, discusses emerging diagnostic and prognostic biomarkers in prostate cancer with Ira M. Klein, MD, MBA, FACP. Dr Klein discusses how results of ongoing trials will be useful to help identify biomarkers to help providers track disease progression.
The integrated cancer services offered by Sarah Cannon will soon be supported by the personalized medicine technology platform of Syapse, to improve individualized patient care, the companies have announced.